icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
March 4-7, 2019
Back grey_arrow_rt.gif
Hormonal Contraceptives Do Not Alter Cabotegravir PK in HIV Uninfected Women: HPTN 077
  Reported by Jules Levin
CROI 2019 March 4-7 Seattle







1. Robinson et al, "Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy" J InfectiDis Obgyn 2012
2. Landolt et al, "Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when co-administered with combined oral contraceptives" JAIDS 2013
3. Vogler et al, "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1–infected women: pharmacokinetic results of ACTG trial A5188" JAIDS 2010
4. Shen et al, "Hormonal contraceptives differentially suppress TFV and TAF inhibition of HIV infection and TFV-DP in blood and genital tract CD4+ t-cells" Scientific Reports 2017 5. Hendrix et al, "Transgender women on estrogen have significantly lower tenofovir/emtricitabine concentrations during directly observed dosing when compared to cis men" HIV R4P 2018
6. Hiransuthikul et al, "Drug-drug interactions between the use of feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study" 22nd International AIDS Conference 2018
7. Trezza et al. "Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in 8. healthy adult women" Br J Clin Pharmacol 2017
9. Landovitz et al, "Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial" PLOS Medicine 2018
10. Bowers et al, "Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans" Xenobiotica 2016


The HIV Prevention Trials Network is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068619, UM1AI068613, UM1AI1068617), with co-funding from the National Institute of Mental Health, and the National Institute on Drug Abuse, all components of the U.S. National Institutes of Health. The work presented here was funded by NIH grants UM1AI068619 (and UM1AI068613 or UM1AI1068617), and study products were provided by ViiV Healthcare. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.